Fig. 5: HDAC inhibitors compromise the function of human T cells.
From: Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics
a, Schematic representation of TCR signaling and cellular outcomes. b, Dose-dependent reduction of the expression of TCR components in response to panobinostat in Jurkat cells. c, Dose-dependent reduction of activation of Jurkat cells in response to HDAC inhibitors. d, Schematic representation of treating human primary T cells with HDAC inhibitors ex vivo. e, The upper panels show microscopic pictures of human primary CD4 positive T cells activated by immobilized anti-CD3 and/or CD28 with or without panobinostat treatment (n = 1). The lower panel shows a bar plot showing the average size of aggregates (shown in the upper panel) as a function of the applied HDAC inhibitor dose. Error bars indicate the standard deviation from n = 5 pictures. *P < 0.05, **P < 0.01, ***P < 0.001 compared to DMSO treatment. Significance testing was done with one-way analysis of variance using F-statistics, followed by calculation of Tukey honest significant differences as post hoc test with confidence interval of 95% and correction for multiple comparisons. Scale bars, 400 μm. f, Dose-dependent expression changes of proteins in human primary T cells treated ex vivo with HDAC inhibitors.
